Arbutus presents clinical trial data from its two hbv assets, imdusiran and ab-101, at the european association for the study of the liver (easl) congress 2025

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis b (chbv) patients when combined with vtp-300 and low dose nivolumab in a phase 1a/1b clinical trial, ab-101, an oral pd-l1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in chbv patients warminster, pa., may 07, 2025 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its rnai therapeutic and ab-101, its oral pd-l1 inhibitor, at the european association for the study of the liver (easl) congress 2025.
ABUS Ratings Summary
ABUS Quant Ranking